The 'no-reflow' phenomenon in cerebral circulation

Medical Science Monitor

Volumn 9, Issue 11, 2003, Pages

  Asiedu Gyekye, Isaac Julius ^a   Vaktorovich, Akadii ^b  

^a UNIVERSITY OF GHANA   (Ghana)

^b VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Enalapril; Ischemia; No reflow

Indexed keywords

ENALAPRIL;

ANASTOMOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN ISCHEMIA; CAT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; HEMOPERFUSION; HYPOTENSION; NONHUMAN;

ANIMALS; ARTERIOVENOUS ANASTOMOSIS; BRAIN; BRAIN ISCHEMIA; CATS; CEREBROVASCULAR CIRCULATION; ENALAPRIL; EXTREMITIES; ISCHEMIA;

EID: 1642442647     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. th edition W.B. Saunders Company, Harcourt Brace Jovanovich, Inc. Philadelphia, USA, 1991; pp 464-8
2. Widimsky P: Reperfusion damage or no-reflow damage in primary coronary interventions in acute myocardial infarction? Eur Heart J. 2002 Jul; 23(14): 1076-8
3. Antoniucci D, Valenti R, Migliorini A et al: Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J. 2001 Oct; 142(4): 684-90
4. Kuhn H, Gietzen F, Leuner C: The abrupt no-flow: a no-reflow like phenomenon in hypertrophic cardiomyopathy. Eur Heart J. 2002 Jan; 23(1): 91-3
5. Marzo A, Dal Bo L, Mazzucchelli P et al: Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzeinmittelforschung 2002; 52(4): 233-42
6. Fournier A, Ghitu A, Darabont R. et al. Duality of angiotensin II receptors and risk for stroke and cancer: what is the connection? Presse Med, 1999; 28(17): 918-22
7. Nakashima M: Pilot study of the uricosuric effect of DuP - 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol, 1992; 42: 333-5
8. Vacher E, Richer C, Giudicelli JF: Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens, 1996; 14 (14): 1341-8
9. Kalender B, Ozturk M, Tuncdemir M et al: Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem, 2002; 104(2) 123-30
10. Walter T, Helber U, Bail D et al: Influence of ACE inhibition on myocardial damage, the kallikrien-kinin system and hemostasis during cardiopulmonary bypass surgery. Thorac Cardiovasc Surg, 2002 Jun; 50(3): 150-4
11. Videbech P, Ravnkilde B, Pedersen TH et al: The Danish PET/depression project: clinical symptoms and cerebral blood flow. A region-of-interest analysis. Acta Psychiatr Scand, 2002 Jul; 106(1): 35-44
12. Asiedu-Gyekye I, Gaevy M: Effect of losartan on cerebral blood flow and its autoregulation in spontaneously hypertensive rats before and after cerebral ischaemia Ghana Science Journal 2001; 3(1): 76-82
13. Gaevy M.D. Maltsev V.G.: The method of Resistograph. Bull Exp Biol and Med, 1977; 5: 634-5
14. Negovsky VA, Gurvich AM, Zolotokripina ES: Post-reanimatory diseases. Medicine, 1987; p. 480
15. PROGRESS collaborative study group. Randomised trial of Perindopril-based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet, 2001; 358: 1033-1041 RT
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA, 2002; 288: 2981-2997. RT
17. Dahlof B, Devereux RB, Kjeldsen SE et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002; 359: 995-1003. RT
18. Lindholm LH, Ibsen H, Dahlof B et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002; 359: 1004-1010. RT
19. Cuspid C, Muiesan ML, Valagussa L et al on behalf of the CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J. Hypertens, 2002; 20: 2293-2300. RT
20. Lithell H, Hansson L, Skogg I et al for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens, 2003; 21; 875-886